醋酸甲羟孕酮联合化疗治疗转移性乳腺癌疗效观察

摘要

Objective To evaluate the efficiency toxicity of medroxyprogesterone acetate combined with chemotherapy ( docetaxel + carboplatin) therapy for metastatic breast cancer.Methods Sixty patients with metastatic breast cancer were randomly divided into MTC group ( n =30) and TC group ( n =30 ).MTC group applied MTC scheme,in particular:medroxyprogesterone acetate 0.5,po,bid,d1-21,docetaxel 75 mg/m2,d1,carboplatin AUC 5 (300-400 mg/m2 ),d2,Intravenous drip,21 days for a cycle; TC group applied TC scheme,in particular:docetaxel 75 mg/m2,dl,carboplatin AUC 5 (300-400 mg/m2 ),d2,intravenous drip,21 days for a cycle.Every patients were cured six cycle.Results MTC group:CR10 cases,PR16 cases,SD4 cases,PD0 case,the total effective rate was 86.7％ ; TC Group:CR7 cases,PR12 cases,SD9 cases,PD2 cases,total effective rate was 63.3％,a significant difference between the two groups(P ＜0.05) ; MTC group one year survival rate was 90.0％ (27/30),TC group one year survival rate was 66.7 ％ (20/30).There were significant differences between the two groups (P ＜ 0.05 ) ; MTC group Ⅲ,Ⅳ leukocytes reduce accounted for 13.3 ％,increased food intake accounted for 80.0％ (24/30),weight gain accounted for 86.7％ (26/30),KPS score increase accounted for 66.7％ (20/30),TC group Ⅲ,Ⅳ leukocytes reduce accounted for 36.7％,increased food intake accounted for 6.7％ (2/30),weight gain accounted for 16.7％ (5/30),KPS score increase accounted for 20％ (6/30).Conclusion Medroxyprogesterone acetate combined with chemotherapy( docetaxel + carboplatin) therapy for metastatic breast cancer to further improve efficiency and prolong survival,toxicity was significantly reduced.%目的 评价醋酸甲羟孕酮联合化疗(多西他赛+卡铂)治疗转移性乳腺癌的疗效和毒副反应.方法 将60例转移性乳腺癌患者完全随机分为MTC组(n=30)和TC组(n=30).MTC组应用MTC方案,具体为:醋酸甲羟孕酮0.25 g,口服,2次/d,d1～21；多西他赛75 mg/m2,d1,卡铂AUC 5(300～400 mg/m2),d2,静脉滴注,21 d为1个周期.TC组应用TC方案,具体为:多西他赛75 mg/m2,d1；卡铂AUC 5 (300～400 mg/m2),d2,静脉滴注,21 d为1个周期.2组患者均治疗6个周期.结果 MTC组:CR 10例,PR16例,SD 4例,PD 0例,总有效率86.7％；TC组:CR 7例,PR 12例,SD 9例,PD 2例,总有效率63.3％,2组差异有统计学意义(P ＜0.05)；MTC组1年生存率90.0％(27/30),TC组1年生存率66.7％(20/30),2组差异有统计学意义(P＜0.05)；MTC组Ⅲ、Ⅳ度白细胞下降率为13.3％,食量增加80.0％(24/30),体重增加86.7％(26/30),KPS评分增加占66.7％(20/30),TC组Ⅲ、Ⅳ度白细胞下降率为36.7％,食量增加6.7％(2/30),体重增加16.7％(5/30),KPS评分增加占20％(6/30).结论 醋酸甲羟孕酮联合化疗(多西他赛+卡铂)治疗转移性乳腺癌可使治疗有效率进一步提高,患者生存率延长,毒副反应明显减轻.